Payment overview · 2025
General Payments
$311.09
20 reported records · 8 companies
Healthcare provider profile · identity verified
Jacquelyn Kirby, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · GREENVILLE, KY · NPI 1053509729
Verified facts
What the public records show
CMS Open Payments records show Jacquelyn Kirby, APRN received $311.09 in general payments during 2025 across 20 reported records.
Amgen Inc. accounted for 45.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $142.39 | 45.8% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.04 | 17.7% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.78 | 9.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.03 | 7.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.19 | 5.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.17 | 4.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.63 | 4.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.86 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $311.09 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $78.48 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $78.48 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $63.91 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $55.04 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $28.78 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $27.89 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
103 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 452 | 86 |
| Metformin Hcl | Metformin Hcl | 411 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 402 | 72 |
| Lisinopril | Lisinopril | 367 | 75 |
| Ezetimibe | Ezetimibe | 331 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 322 | 73 |
| Omeprazole | Omeprazole | 286 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 260 | 52 |
| Furosemide | Furosemide | 241 | 43 |
| Glipizide | Glipizide | 228 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 213 | 37 |
| Buspirone Hcl | Buspirone Hcl | 210 | 37 |
| Atenolol | Atenolol | 195 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 182 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 175 | 41 |
| Lovastatin | Lovastatin | 173 | 29 |
| Enalapril Maleate | Enalapril Maleate | 169 | 34 |
| Simvastatin | Simvastatin | 166 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 160 | 34 |
| Gabapentin | Gabapentin | 159 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 147 | 45 |
| Glimepiride | Glimepiride | 147 | 29 |
| Losartan Potassium | Losartan Potassium | 140 | 30 |
| Montelukast Sodium | Montelukast Sodium | 135 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 129 | 20 |
| Carvedilol | Carvedilol | 128 | 27 |
| Allopurinol | Allopurinol | 127 | 22 |
| Jardiance | Empagliflozin | 124 | 17 |
| Trazodone Hcl | Trazodone Hcl | 121 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 116 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 111 | 21 |
| Potassium Chloride | Potassium Chloride | 110 | 18 |
| Meloxicam | Meloxicam | 108 | 22 |
| Famotidine | Famotidine | 107 | 19 |
| Sertraline Hcl | Sertraline Hcl | 104 | 20 |
| Farxiga | Dapagliflozin Propanediol | 103 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 96 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 84 | 17 |
| Spironolactone | Spironolactone | 84 | 11 |
| Januvia | Sitagliptin Phosphate | 80 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 74 | 26 |
| Warfarin Sodium | Warfarin Sodium | 72 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 71 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 65 | 18 |
| Celecoxib | Celecoxib | 63 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | suppressed |
| Rybelsus | Semaglutide | 45 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Alprazolam | Alprazolam | 40 | suppressed |
| Azithromycin | Azithromycin | 40 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | 11 |
| Tramadol Hcl | Tramadol Hcl | 39 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Eliquis | Apixaban | 37 | suppressed |
| Gemfibrozil | Gemfibrozil | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 14 |
| Digoxin | Digoxin | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Glyburide | Glyburide | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Prednisone | Prednisone | 25 | 17 |
| Finasteride | Finasteride | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 12 |
| Pregabalin | Pregabalin | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Verapamil Sr | Verapamil Hcl | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 16 |
| Baclofen | Baclofen | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $311.09 · 20 records | Amgen Inc. | Auvelity, EVENITY, Kerendia, LEQVIO, MOUNJARO, OTEZLA, PROLIA, REPATHA, VOQUEZNA, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error